Abstract: SA-PO714
Usefulness of Urinary-Soluble CD163 as a Biomarker of Disease Activity in Patients with Glomerulonephritis
Session Information
- Pathology and Lab Medicine: Clinical
November 09, 2019 | Location: Exhibit Hall, Walter E. Washington Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Pathology and Lab Medicine
- 1602 Pathology and Lab Medicine: Clinical
Authors
- Yamazaki, Hidenori, The Second Department of Internal Medicine, University of Toyama, Toyama, Japan
- Koike, Tsutomu, The Second Department of Internal Medicine, University of Toyama, Toyama, Japan
- Fujioka, Hayato, The Second Department of Internal Medicine, University of Toyama, Toyama, Japan
- Kakeshita, Kota, The Second Department of Internal Medicine, University of Toyama, Toyama, Japan
- Kobayashi, Shiori, The Second Department of Internal Medicine, University of Toyama, Toyama, Japan
- Takashima, Ayako, The Second Department of Internal Medicine, University of Toyama, Toyama, Japan
- Kinugawa, Koichiro, The Second Department of Internal Medicine, University of Toyama, Toyama, Japan
Background
Although histopathological examination of kidney tissues can be useful for understanding of disease activity of glomerulonephritis, there are undiagnosed cases because of the difficulties in performing invasive biopsies. Therefore, noninvasive biomarkers are needed to reflect disease activity and monitor response to therapy in patients with glomerulonephritis. Recently, it is suggested that the level of urinary soluble CD163 (sCD163), a marker of M2 macrophage infiltration, associated very tightly with active renal vasculitis, but the usefulness of urinary sCD163 as a surrogate marker of disease activity in glomerulonephritis is unclear. In this study, we investigated whether urinary sCD163 is useful for reflecting disease activity and monitoring response to therapy in patients with glomerulonephritis.
Methods
Subjects were forty-five patients with biopsy-proven glomerulonephritis including IgA nephropathy (n=24), IgA vasculitis (n=7), ANCA-associated glomerulonephritis (n=8), and lupus nephritis (n=6). In all patients, urinary excretion of sCD163 and protein, and quantitative urinary occult blood were measured at two points (baseline and follow-up). The relationships between change in urinary sCD163, reflecting follow-up value minus baseline value, and changes in other measurements were evaluated.
Results
Patients except for 8 cases of IgA nephropathy were treated with steroid therapy. At the point of follow-up, urinary sCD163 significantly decreased compared with baseline (6582±10827 to 1837±4510 pg/mgCr, p <0.01). Change in urinary sCD163 positively correlated with change in urinary protein (r = 0.60, p <0.01), whereas change in urinary sCD163 did not associate with change in urinary occult blood. ROC curve analysis revealed that a reduction of urinary sCD163 by more than 60% predicted remission of proteinuria defined as urinary protein < 0.3 g/gCr (71.4% sensitivity and 87.1% specificity), and a reduction of urinary sCD163 by more than 86% predicted remission of hematuria remission (86.4% sensitivity and 54.5% specificity).
Conclusion
Urinary sCD163 levels reflected disease activity of glomerulonephritis and thus may be useful for monitoring disease activity in patients with glomerulonephritis.